{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:48:07Z","timestamp":1790635687178,"version":"4.1.0"},"reference-count":166,"publisher":"Elsevier","isbn-type":[{"value":"9780323957786","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.pbr.2023.01.002","type":"book-chapter","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T15:23:46Z","timestamp":1677770626000},"page":"25-60","source":"Crossref","is-referenced-by-count":12,"title":["Genetics of antidepressant response and treatment-resistant depression"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2023.01.002_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s10038-020-00842-5","article-title":"Multi-omics study for interpretation of genome-wide association study","volume":"66","author":"Akiyama","year":"2021","journal-title":"J. Hum. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0015","first-page":"57","article-title":"Suicide risk in patients with major depressive disorder","volume":"60","author":"Angst","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00702-007-0705-9","article-title":"Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression","volume":"114","author":"Anttila","year":"2007","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e32831ebb4b","article-title":"Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors","volume":"19","author":"Arias","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD)\u2014basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders","volume":"14","author":"Bauer","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biopsych.2009.11.004","article-title":"The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression","volume":"67","author":"Baune","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archgenpsychiatry.2010.18","article-title":"Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response","volume":"67","author":"Binder","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF\u2014a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neulet.2008.04.005","article-title":"5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression","volume":"437","author":"Bocchio-Chiavetto","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0060","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.pnpbp.2010.04.020","article-title":"Serotonin transporter gene polymorphisms and treatment-resistant depression","volume":"34","author":"Bonvicini","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.2018.18070881","article-title":"No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples","volume":"176","author":"Border","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/15622970701308397","article-title":"Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder","volume":"9","author":"Bozina","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pnpbp.2013.03.005","article-title":"Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients","volume":"44","author":"Calati","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0080","first-page":"130","article-title":"Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study","volume":"22","author":"Campos","year":"2022","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/YIC.0000000000000386","article-title":"Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence","volume":"37","author":"Cellini","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1758-5872.2012.00219.x","article-title":"Association between brain-derived neurotrophic factor V 66 M and treatment responses to escitalopram in patients with major depressive disorder","volume":"4","author":"Chang","year":"2012","journal-title":"Asia Pac. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1755-5949.2009.00093.x","article-title":"Biological variations in depression and anxiety between East and West","volume":"15","author":"Chen","year":"2009","journal-title":"CNS Neurosci. Therap."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000087847","article-title":"Serotonin receptor 2A gene polymorphism (-1438A\/G) and short-term treatment response to citalopram","volume":"52","author":"Choi","year":"2005","journal-title":"Neuropsychobiology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2006.08.012","article-title":"Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder","volume":"1118","author":"Choi","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0110","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/s41380-020-00984-0","article-title":"Genome-wide association study of patients with a severe major depressive episode treated with electroconvulsive therapy","volume":"26","author":"Clements","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.30773\/pi.2019.06.16","article-title":"Pharmacogenetics and depression: a critical perspective","volume":"16","author":"Corponi","year":"2019","journal-title":"Psychiatry Investig."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/0269881111434622","article-title":"Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder","volume":"26","author":"Cutler","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","article-title":"Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: a systematic review","volume":"240","author":"De Carlo","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pnpbp.2019.01.001","article-title":"Duloxetine plasma level and antidepressant response","volume":"92","author":"De Donatis","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1461145709000030","article-title":"Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response","volume":"13","author":"Domschke","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajmg.b.30949","article-title":"COMT val158met influence on electroconvulsive therapy response in major depression","volume":"153b","author":"Domschke","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41398-022-02032-7","article-title":"Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial","volume":"12","author":"Engelmann","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.euroneuro.2012.07.006","article-title":"Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D","volume":"23","author":"Fabbri","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0155","first-page":"463","article-title":"PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway","volume":"14","author":"Fabbri","year":"2014","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00406-017-0766-1","article-title":"Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance","volume":"267","author":"Fabbri","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","article-title":"The genetics of treatment-resistant depression: a critical review and future perspectives","volume":"22","author":"Fabbri","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41398-020-0738-5","article-title":"A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping","volume":"10","author":"Fabbri","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/YIC.0000000000000305","article-title":"Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment","volume":"35","author":"Fabbri","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0180","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41380-021-01062-9","article-title":"Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts","volume":"26","author":"Fabbri","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110170","article-title":"Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder","volume":"108","author":"Fanelli","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euroneuro.2021.11.005","article-title":"A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response","volume":"55","author":"Fanelli","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J3W31F","article-title":"Beta adrenoceptor polymorphism and clinical response to sertraline in major depressive patients","volume":"20","author":"Firouzabadi","year":"2017","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0200","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neubiorev.2017.10.012","article-title":"Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response-meta-analysis","volume":"83","author":"Fischer","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0205","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neubiorev.2018.11.009","article-title":"Polymorphisms in genes related to the hypothalamic-pituitary-adrenal axis and antidepressant response\u2014systematic review","volume":"96","author":"Fischer","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.psychres.2014.04.030","article-title":"Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression","volume":"218","author":"Fukui","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0220","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/pgs-2022-0037","article-title":"The pharmacogenomics of selective serotonin reuptake inhibitors","volume":"23","author":"Garc\u00eda-Mar\u00edn","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.biopsych.2009.08.029","article-title":"A genomewide association study of citalopram response in major depressive disorder","volume":"67","author":"Garriock","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0230","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.2009.08081167","article-title":"Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder","volume":"167","author":"Garriock","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0235","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajmg.b.30646","article-title":"Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder","volume":"147b","author":"Gau","year":"2008","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0240","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1176\/appi.ajp.2012.12020237","article-title":"Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies","volume":"170","author":"GENDEP Investigators, M. I., STAR*D Investigators","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0250","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamapsychiatry.2021.2099","article-title":"The genetic architecture of depression in individuals of east asian ancestry: a genome-wide association study","volume":"78","author":"Giannakopoulou","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0255","first-page":"126","article-title":"Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine","volume":"10","author":"Glubb","year":"2010","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pnpbp.2006.08.001","article-title":"Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population","volume":"31","author":"Ham","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0265","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4306\/pi.2013.10.3.286","article-title":"CYP2D6 P34S polymorphism and outcomes of escitalopram treatment in koreans with major depression","volume":"10","author":"Han","year":"2013","journal-title":"Psychiatry Investig."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/gm351","article-title":"Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response","volume":"4","author":"Hodgson","year":"2012","journal-title":"Genome Med."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0280","first-page":"27","article-title":"Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder","volume":"6","author":"Hong","year":"2006","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/npp.2009.180","article-title":"Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment","volume":"35","author":"Horstmann","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions","volume":"22","author":"Howard","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00406-010-0126-x","article-title":"Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?","volume":"261","author":"Illi","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0300","author":"Institute of Health Metrics and Evaluation"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0305","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archgenpsychiatry.2009.95","article-title":"A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression","volume":"66","author":"Ising","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0310","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/gps.3899","article-title":"Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression","volume":"28","author":"Jamerson","year":"2013","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0315","first-page":"78","article-title":"Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response","volume":"12","author":"Ji","year":"2012","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0320","first-page":"456","article-title":"Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics","volume":"13","author":"Ji","year":"2013","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41398-019-0589-0","article-title":"Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants","volume":"9","author":"Ju","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0330","article-title":"Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits","author":"Kang","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0335","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000094727","article-title":"Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients","volume":"53","author":"Kato","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0340","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neulet.2015.01.077","article-title":"Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression","volume":"590","author":"Kautto","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0345","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.euroneuro.2015.01.001","article-title":"The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression","volume":"25","author":"Kautzky","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0350","doi-asserted-by":"crossref","first-page":"13579","DOI":"10.4088\/JCP.15m10381","article-title":"A new prediction model for evaluating treatment-resistant depression","volume":"78","author":"Kautzky","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0355","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2217\/pgs.14.96","article-title":"GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis","volume":"15","author":"Kawaguchi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11920-011-0251-x","article-title":"Gene\u2013environment interaction in major depression and antidepressant treatment response","volume":"14","author":"Keers","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12017-009-8060-7","article-title":"CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients","volume":"11","author":"Kishi","year":"2009","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12017-009-8105-y","article-title":"HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort","volume":"12","author":"Kishi","year":"2010","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0375","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1017\/S1461145712001459","article-title":"Gene\u00d7environment interactions in the prediction of response to antidepressant treatment","volume":"16","author":"Klengel","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0380","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.biopsych.2005.04.048","article-title":"Sequence analysis of the serotonin transporter and associations with antidepressant response","volume":"58","author":"Kraft","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0385","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2006.07.017","article-title":"Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample","volume":"61","author":"Kraft","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0390","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0395","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/JCP.0b013e3181d2ef42","article-title":"MRP1 polymorphisms associated with citalopram response in patients with major depression","volume":"30","author":"Lee","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0400","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2007.10.026","article-title":"The FKBP5-gene in depression and treatment response\u2014an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort","volume":"63","author":"Lekman","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0405","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychires.2012.10.003","article-title":"The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice","volume":"47","author":"Li","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0410","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JCP.0000000000000119","article-title":"SLC17A7 gene may be the indicator of selective serotonin reuptake inhibitor treatment response in the Chinese Han population","volume":"34","author":"Li","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0415","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41398-020-01035-6","article-title":"Genome-wide association studies of antidepressant class response and treatment-resistant depression","volume":"10","author":"Li","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107098","article-title":"Genetic prediction of antidepressant drug response and nonresponse in Korean patients","volume":"9","author":"Lim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0425","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2217\/pgs.10.128","article-title":"CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine","volume":"11","author":"Lin","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/FPC.0b013e32833db216","article-title":"ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment","volume":"21","author":"Lin","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0435","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s12013-014-0361-2","article-title":"Influence of Val108\/158Met COMT gene polymorphism on the efficacy of modified electroconvulsive therapy in patients with treatment resistant depression","volume":"71","author":"Lin","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0440","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/FPC.0b013e32832cbe61","article-title":"Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment","volume":"19","author":"Liou","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0445","first-page":"677","article-title":"PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders","volume":"6","author":"Liu","year":"2013","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0450","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1038\/s41380-020-00940-y","article-title":"ERICH3: vesicular association and antidepressant treatment response","volume":"26","author":"Liu","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0455","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.euroneuro.2009.08.006","article-title":"HTR2A gene variation is involved in antidepressant treatment response","volume":"20","author":"Lucae","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0460","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/da.20815","article-title":"Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation","volume":"28","author":"Malaguti","year":"2011","journal-title":"Depress. Anxiety"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0465","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00228-016-2099-9","article-title":"Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients","volume":"72","author":"Manoharan","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0470","first-page":"459","article-title":"DNA methylation of fluoxetine response in child and adolescence: preliminary results","volume":"14","author":"Martinez-Pinte\u00f1o","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0480","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/503820","article-title":"Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment","volume":"78","author":"McMahon","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2022.02.015","article-title":"The potential of polygenic risk scores to predict antidepressant treatment response in major depression: a systematic review","volume":"304","author":"Meerman","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0490","doi-asserted-by":"crossref","DOI":"10.1017\/S0016672315000142","article-title":"The role of GRIK4 gene in treatment-resistant depression","volume":"97","author":"Milanesi","year":"2015","journal-title":"Genet Res. (Camb.)"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0495","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00213-009-1550-3","article-title":"Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response","volume":"205","author":"Min","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0500","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neulet.2016.05.030","article-title":"Influence of GRIK4 genetic variants on the electroconvulsive therapy response","volume":"626","author":"Minelli","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0505","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-013-2995-y","article-title":"Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment","volume":"227","author":"Mitjans","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0510","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajmg.b.30816","article-title":"SLC6A4 variation and citalopram response","volume":"150b","author":"Mrazek","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0515","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00213-012-2813-y","article-title":"Serotonin transporter genotype and function in relation to antidepressant response in Koreans","volume":"225","author":"Myung","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0520","series-title":"A Systematic Review of Candidate Genes for Major Depression","first-page":"58","author":"Norkeviciene","year":"2022"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1176\/appi.neuropsych.16120322","article-title":"Glucocorticoid receptor genetic variants and response to fluoxetine in major depressive disorder","volume":"30","author":"Nouraei","year":"2018","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0530","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopsych.2013.10.028","article-title":"Rare copy number variation in treatment-resistant major depressive disorder","volume":"76","author":"O'Dushlaine","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0006-3223(94)90642-4","article-title":"Pharmacogenetic response to antidepressants in a multicase family with affective disorder","volume":"36","author":"O'Reilly","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0540","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bpsgos.2021.07.008","article-title":"Identifying the common genetic basis of antidepressant response","volume":"2","author":"Pain","year":"2022","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0545","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2007.02.017","article-title":"Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment","volume":"104","author":"Papiol","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0550","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s12035-016-9711-y","article-title":"Klotho gene and selective serotonin reuptake inhibitors: response to treatment in late-life major depressive disorder","volume":"54","author":"Paroni","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0555","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/npp.2008.6","article-title":"Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study","volume":"33","author":"Perlis","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0560","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.mp.4001502","article-title":"Investigation of serotonin-related genes in antidepressant response","volume":"9","author":"Peters","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e3283163ecd","article-title":"Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response","volume":"19","author":"Peters","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0570","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0575","first-page":"548","article-title":"DNA copy number variation: main characteristics, evolutionary significance, and pathological aspects","volume":"44","author":"P\u00f6s","year":"2021","journal-title":"Biom. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0580","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/pgs.13.1","article-title":"Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response","volume":"14","author":"Pu","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0755","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"Purcell","year":"2009","journal-title":"Nature"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0585","doi-asserted-by":"crossref","first-page":"14242","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0590","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0595","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/mp.2011.144","article-title":"Genome-wide association analysis of copy number variation in recurrent depressive disorder","volume":"18","author":"Rucker","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0600","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jad.2011.02.020","article-title":"Staging methods for treatment resistant depression. A systematic review","volume":"137","author":"Ruh\u00e9","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0605","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neubiorev.2021.12.008","article-title":"The neurobiology of treatment-resistant depression: a systematic review of neuroimaging studies","volume":"132","author":"Runia","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0610","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5498\/wjp.v12.i7.884","article-title":"Genetic variables of the glutamatergic system associated with treatment-resistant depression: a review of the literature","volume":"12","author":"Saez","year":"2022","journal-title":"World J Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0615","first-page":"86","article-title":"Serotonin Transporter Polymorphism (5-HTTLPR) and citalopram effectiveness in iranian patients with major depressive disorder","volume":"8","author":"Sahraian","year":"2013","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0620","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.5498\/wjp.v12.i9.1150","article-title":"Depressive disorder and antidepressants from an epigenetic point of view","volume":"12","author":"\u0160alamon Ar\u010dan","year":"2022","journal-title":"World J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0625","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.mp.4001926","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients","volume":"12","author":"Serretti","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0630","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jad.2010.06.025","article-title":"A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression","volume":"128","author":"Serretti","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0635","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000329553","article-title":"Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression","volume":"65","author":"Serretti","year":"2012","journal-title":"Neuropsychobiology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0640","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674371005500303","article-title":"The sequenced treatment alternatives to relieve depression (STAR* D) trial: a review","volume":"55","author":"Sinyor","year":"2010","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0645","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.psychres.2018.12.053","article-title":"Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?","volume":"271","author":"Solomon","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0650","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081993","article-title":"Systems approach to identify common genes and pathways associated with response to selective serotonin reuptake inhibitors and major depression risk","volume":"20","author":"Srivastava","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0655","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0660","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.biopsych.2017.09.004","article-title":"How good were candidate gene guesses in schizophrenia genetics?","volume":"82","author":"Sullivan","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0665","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1176\/appi.ajp.157.10.1552","article-title":"Genetic epidemiology of major depression: review and meta-analysis","volume":"157","author":"Sullivan","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0670","first-page":"283","article-title":"The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients","volume":"4","author":"Suzuki","year":"2004","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0675","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrg796","article-title":"Candidate-gene approaches for studying complex genetic traits: practical considerations","volume":"3","author":"Tabor","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0680","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41398-021-01488-3","article-title":"Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data","volume":"11","author":"Taliaz","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144333","article-title":"Association between COMT gene Val108\/158Met and antidepressive treatment response: a meta-analysis","volume":"734","author":"Tang","year":"2020","journal-title":"Gene"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0690","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2012.10.030","article-title":"Contribution of common genetic variants to antidepressant response","volume":"73","author":"Tansey","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0695","first-page":"395","article-title":"Copy number variants and therapeutic response to antidepressant medication in major depressive disorder","volume":"14","author":"Tansey","year":"2014","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0700","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopsych.2010.04.034","article-title":"Antidepressant response and the serotonin transporter gene-linked polymorphic region","volume":"68","author":"Taylor","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0705","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0710","first-page":"384","article-title":"Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder","volume":"8","author":"Tsai","year":"2008","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0715","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jad.2008.04.017","article-title":"Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients","volume":"113","author":"Tsai","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0720","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pnpbp.2009.02.020","article-title":"Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response","volume":"33","author":"Tsai","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0725","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4306\/pi.2010.7.4.236","article-title":"Effects of BDNF polymorphisms on antidepressant action","volume":"7","author":"Tsai","year":"2010","journal-title":"Psychiatry Investig."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005403","article-title":"A new method for detecting associations with rare copy-number variants","volume":"11","author":"Tzeng","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0735","first-page":"225","article-title":"Genetic predictors of response to antidepressants in the GENDEP project","volume":"9","author":"Uher","year":"2009","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0740","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1176\/appi.ajp.2009.09070932","article-title":"Genome-wide pharmacogenetics of antidepressant response in the GENDEP project","volume":"167","author":"Uher","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0745","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12888-014-0220-0","article-title":"Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study","volume":"14","author":"Ventura-Junc\u00e1","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0750","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.161.3836.72","article-title":"Genetic control of drug levels in man: antipyrine","volume":"161","author":"Vesell","year":"1968","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0760","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0765","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.psychres.2012.06.024","article-title":"The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment","volume":"200","author":"Wang","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0770","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/FTD.0000000000000062","article-title":"Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population","volume":"36","author":"Wang","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0775","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2015.07.011","article-title":"Evidence for the role of corticotropin-releasing factor in major depressive disorder","volume":"58","author":"Waters","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0780","article-title":"Strategies for pathway analysis using GWAS and WGS data","volume":"100","author":"White","year":"2019","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0785","first-page":"329","article-title":"Genome-wide association study of antidepressant treatmentresistance in a population-based cohort using health service prescription data andmeta-analysis with GENDEP","volume":"20","author":"Wigmore","year":"2020","journal-title":"Pharm. J."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0790","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/mp.2008.59","article-title":"Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response","volume":"13","author":"Wong","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0795","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/0269881111414452","article-title":"Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response","volume":"26","author":"Xu","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0800","series-title":"TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs","first-page":"19","author":"Xu","year":"2016"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0805","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.genhosppsych.2012.05.015","article-title":"Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population","volume":"34","author":"Yang","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0810","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/appy.12180","article-title":"Catecholamine pathway polymorphisms and antidepressant response","volume":"8","author":"Yin","year":"2016","journal-title":"Asia Pac. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0815","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0278-5846(01)00287-1","article-title":"Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients","volume":"26","author":"Yoshida","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0820","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.npp.1300172","article-title":"Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response","volume":"28","author":"Yu","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2023.01.002_bb0825","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.euroneuro.2005.12.004","article-title":"Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders","volume":"16","author":"Yu","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2023.01.002_bb0830","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00213-013-3297-0","article-title":"A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression","volume":"231","author":"Zhang","year":"2014","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.pbr.2023.01.002_bb0835","doi-asserted-by":"crossref","first-page":"20m13699","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"}],"container-title":["Progress in Brain Research","Treatment-Resistant Depression Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007961232300002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007961232300002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:59:47Z","timestamp":1754427587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007961232300002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323957786"],"references-count":166,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2023.01.002","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}